J Neurosci:新标志物有助诊断阿尔茨海默病

2012-06-18 陈蓉 生物谷

       近日,波士顿大学医学院(BUSM)研究人员确定阿尔茨海默病患者大脑中一种积聚的蛋白质组。这些调查结果发表在Journal of Neuroscience杂志上,该研究可能有助开辟新的方法来诊断治疗阿尔茨海默病患者。[J Neurosci 2012 Jun 13;32(24):8270-83]       &n

       近日,波士顿大学医学院(BUSM)研究人员确定阿尔茨海默病患者大脑中一种积聚的蛋白质组。这些调查结果发表在Journal of Neuroscience杂志上,该研究可能有助开辟新的方法来诊断治疗阿尔茨海默病患者。[J Neurosci 2012 Jun 13;32(24):8270-83]

       β-淀粉样蛋白聚集诱导神经元蛋白质聚集引起阿尔茨海默氏病,阿尔茨海默氏病是一种神经退行性疾病。阿尔茨海默氏病的诊断对象主要是β-淀粉样蛋白和tau蛋白,主要用放射性标记物来结合β-淀粉样蛋白。然而β-淀粉样蛋白的成像是有问题的,因为许多认知正常的老年人大脑中也有大量的β-淀粉样蛋白,因此检测结果中会出现阳性结果。

       BUSM研究人员发现新的蛋白质组称为RNA结合蛋白,该蛋白也在阿尔茨海默氏症患者大脑中积累,尤其是在那些认知能力低于正常水平的老年人。该研究小组发现蛋白质如TIA-1和TTP聚集,诱导tau蛋白在神经元聚集。Benjamin Wolozin博士解释说:这些蛋白质还结合tau,可能参与疾病的发生发展过程。一个不同的RNA结合蛋白——G3BP聚集在神经元中,但不会诱导病理性tau蛋白聚集。

        研究人员认为这项工作量化这些RNA结合蛋白这一生物标志物有利于开辟新的方法来诊断治疗阿尔茨海默氏症患者。
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1840740, encodeId=16d51840e404d, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Oct 01 01:47:00 CST 2012, time=2012-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817551, encodeId=0cf1181e5514d, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Dec 08 05:47:00 CST 2012, time=2012-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816528, encodeId=df2f1816528f8, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Apr 23 22:47:00 CST 2013, time=2013-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363854, encodeId=3a32136385484, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 20 09:47:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469905, encodeId=0c3f14699058e, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jun 20 09:47:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1840740, encodeId=16d51840e404d, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Oct 01 01:47:00 CST 2012, time=2012-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817551, encodeId=0cf1181e5514d, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Dec 08 05:47:00 CST 2012, time=2012-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816528, encodeId=df2f1816528f8, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Apr 23 22:47:00 CST 2013, time=2013-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363854, encodeId=3a32136385484, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 20 09:47:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469905, encodeId=0c3f14699058e, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jun 20 09:47:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1840740, encodeId=16d51840e404d, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Oct 01 01:47:00 CST 2012, time=2012-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817551, encodeId=0cf1181e5514d, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Dec 08 05:47:00 CST 2012, time=2012-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816528, encodeId=df2f1816528f8, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Apr 23 22:47:00 CST 2013, time=2013-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363854, encodeId=3a32136385484, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 20 09:47:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469905, encodeId=0c3f14699058e, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jun 20 09:47:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1840740, encodeId=16d51840e404d, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Oct 01 01:47:00 CST 2012, time=2012-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817551, encodeId=0cf1181e5514d, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Dec 08 05:47:00 CST 2012, time=2012-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816528, encodeId=df2f1816528f8, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Apr 23 22:47:00 CST 2013, time=2013-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363854, encodeId=3a32136385484, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 20 09:47:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469905, encodeId=0c3f14699058e, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jun 20 09:47:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
    2012-06-20 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1840740, encodeId=16d51840e404d, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Oct 01 01:47:00 CST 2012, time=2012-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817551, encodeId=0cf1181e5514d, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Dec 08 05:47:00 CST 2012, time=2012-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816528, encodeId=df2f1816528f8, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Apr 23 22:47:00 CST 2013, time=2013-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363854, encodeId=3a32136385484, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Jun 20 09:47:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469905, encodeId=0c3f14699058e, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Wed Jun 20 09:47:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]

相关资讯

Lancet Neurol:AD新疫苗人体试验显成效

      《柳叶刀·神经学》杂志于2012年6月6日在线发表的一项随机、双盲、安慰剂对照的首次人体试验研究表明,CAD106(疫苗)对于阿尔茨海默病(AD)患者来说,具有良好的安全性且其抗体反应程度可以接受。【Lancet Neurol. 2012 Jun 1. 】   以β淀粉样蛋白(Aβ)为靶点的免疫治疗是减缓阿尔茨海默病进展的一项后备策略。该研

JAD:大脑成像新技术MRS有助阿尔茨海默病早期诊断

阿尔茨海默症(AD)是主要的神经退行性疾病之一,全球数百万人因该疾病而受到不同程度的影响。寻找新的、更精确的诊断方法对于该疾病的早期诊断尤为关键。 近日,Pravat K. Mandal博士和他的同事们共同研究开发出一种完全无创的大脑成像技术,利用该技术可以测出脑内某些特殊化学物质的变化,这为病变于大脑海马区AD的早期诊断拉开了序曲。研究论文发表于《阿尔茨海默症》杂志(Journal of Al

β-淀粉样蛋白相关认知功能减退在什么时候出现?

     《神经病学文献》(Archives of Neurology)4月23日在线发表的一项研究显示,在临床正常的老年人中,与脑脊液高β淀粉样蛋白水平相关的认知功能减退仅在磷酸化Tau蛋白(p-tau)水平也升高的情况下才出现【Arch. Neurol. 2012 April 23 [doi:10.1001/archneurol.2011.3354]】。

2012 AAN年会:多发性硬化的临床过程不受绝经的影响

       2012年4月21-28日,第64届美国神经病学会年会在美国新奥尔良召开。会上,研究者报告,多发性硬化(MS)的临床过程似乎不受绝经的影响。   美国哈佛大学医学院布莱根和妇女医院MS中心的Riley Bove博士报告,绝经前和绝经女性扩展残疾状况量表评分2年内分别升高0.139和0.122分(P=0.8

cell综述:阿尔茨海默病30年来的研究进展

      来自加州大学旧金山分校,Gladstone神经疾病研究所的Lennart Mucke和黄亚东教授发表了题为“Alzheimer Mechanisms and Therapeutic Strategies”的文章,总结概括了过去三十年里,这一疾病的发展,指出这一领域的研究探讨和药物研发,应该多元化发展,来解析阿尔茨海默病这一多因素影响

阿尔茨海默病的脑微出血研究进展

【摘要】     阿尔茨海默病(AD)患者的脑微出血研究近来备受重视,因为病理学基础是脑淀粉样 血管病(CAA)。CAA作为衔接AD淀粉样蛋白假说和血管异常机制的核心病理学表现,近年来的临床病理学研究结果提示高度重视AD患者的CAA所致CMB情况,对于临床患者的管理和临床试验的指标设计有指导意义。 1. 脑微出血概念、病理特点及临床意义   &nb